First Nitinol Stent in the U.S. Indicated for Primary Stenting of Common and External Iliac Arteries, Stenting of Superficial Artery (SFA) and Proximal Popliteal Artery (PPA)

S.M.A.R.T.® Vascular Stent Systems Clinical Outcomes in the SFA1

  1 year 2 years
Freedom from target lesion revascularization (TLR) 87.6% 80.3%
Primary patency rate 81.7%2 74.9%2
DUS patency 81.1% 83.5%
Fracture rate 2.0% (least severe Type I only) No additional fractures between year 1 and 2

S.M.A.R.T.® Vascular Stent Systems Patient Outcomes in the SFA1

  1 year 2 years
Minimal or no signs of PAD 76.6%3 81.8%3
Normal ABI 81.0% 80.7%

1From STROLL Trial Results, Data on File, Cordis Corporation
2Defined as no significant reduction in flow detectable by duplex ultrasound and no further clinically driven TLR
3Defined as Rutherford Becker classification 0 or 1

S.M.A.R.T.® Vascular Stent Systems Outcomes in the Iliacs*

  • 95% primary patency, 12 months
  • 7% Adverse Event rate, 9 months+
  • 3.5% binary restenosis, 9 months

S.M.A.R.T.® Vascular Stent Systems Deliver Notable Patient Results in the Iliacs*

  • 30% improvement in ABI
  • Patients Can Walk With Less Pain**
  • 58% Improvement in Walking Questionnaire Score
  • Observed Improvement in Walking Distance

S.M.A.R.T.® Vascular Stent Systems – Design is Key

Smaller cell size and uniform coverage can prevent vessel prolapsed.

Longitudinal stability
Greater stability minimizes stretching at deployment, thereby increasing placement accuracy.

Radial force
The stent’s ability to resist compression maintains luminal gain.

Unique 36 Strut/6 Bridge Construction

6 alternating bridges
Each ring is connected by 6 bridges for greater longitudinal stability.

36 struts
Each circumferential ring contains 36 struts, providing radial force and scaffolding.

Offset peak-to-valley design
The offset design provides smooth lumen and stent contourability without strut overlapping or fish scaling.

Segmented micromesh geometry
The unique micromesh design allows for consistent radial force, uniform scaffolding, and small cell size.

*From CRISP Trial Results, 12 month follow-up
**Based on Rutherford-Becker Scale classification pre-procedure versus 9-month follow-up
+Composite of binary restenosis, death at 30 days and TVR